At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
human umbilical cord mesenchymal stem cells (hUC-MSCs)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Repeated Subarachnoid Administrations of Human Umbilical Cord Mesenchymal Stem Cells in Treating Spinal Cord Injury
In Brief
A Phase 2 clinical trial evaluating human umbilical cord mesenchymal stem cells (hUC-MSCs) for Spinal Cord Injuries. Completed, enrolled 102 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of repeated intrathecal administrations of allogeneic human umbilical cord mesenchymal stem cells for the treatment of spinal cord injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartMar 2018
Primary CompletionMar 2020
TodayJul 2026
First PostedJun 25, 2015
Enrollment StartMar 30, 2018
Primary CompletionMar 31, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.0 years ago
Interventions
human umbilical cord mesenchymal stem cells (hUC-MSCs)biological
Four times of intrathecal administrations of hUC-MSCs